MetaCap

Definium Therapeutics (DFTX) vs Altria Group (MO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Definium Therapeutics (DFTX) has outperformed Altria Group (MO) over the past year, gaining 193.1% versus a gain of 4.0%. Over five years, MO leads with a +42.3% price change compared with -0.5% for DFTX. Altria Group is the larger company by market cap ($115.85 billion vs $4.71 billion), about 24.6 times the size.

Altria Group pays a dividend yielding 6.11%, while Definium Therapeutics does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DFTX+187.15%MO+6.00%
+312%+140%-32%
Oct 6, 20251 yearOct 7, 2026
DFTX+4.43%MO+48.28%
+67%-17%-101%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DFTX versus MO key metrics
MetricDFTXMO
Share price$35.09$69.38
Market cap$4.71B$115.85B
1-day change-1.49%+1.21%
YTD return+162.06%+20.17%
1-year return+193.15%+3.96%
5-year return-0.45%+42.28%
P/E ratio (TTM)—14.61
Forward P/E—11.83
EPS (TTM)$-3.43$4.75
Dividend yield0.00%6.11%
Annual dividend$0.00$4.24
Revenue (latest FY)—$23.28B
Revenue growth (YoY)—-3.08%
Net income (latest FY)$-183.79M$6.95B
Gross margin—62.47%
Operating margin—42.52%
Net margin—29.84%
52-week high$49.70$77.06
52-week low$10.47$54.70
Distance from 52-week high-29.40%-9.97%
Analyst consensusnonehold
Avg. price target upside+104.19%+0.89%
Average volume2.15M8.46M
Shares outstanding134.37M1.67B
Employees1055,900
SectorHealth CareHealth Care
Industry Medicinal Chemicals and Botanical Products Medicinal Chemicals and Botanical Products

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Altria Group is about 24.6 times larger than Definium Therapeutics by market value ($115.85B vs $4.71B).
  • DFTX has outperformed MO by 189.2 percentage points over the past year.
  • Altria Group offers a meaningfully higher dividend yield (6.11% vs 0.00%).

About Definium Therapeutics

DFTX stock →

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.

Health Care · Medicinal Chemicals and Botanical Products · 105 employees

About Altria Group

MO stock →

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. It offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and oral tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand.

Health Care · Medicinal Chemicals and Botanical Products · 5,900 employees

DFTX vs MO FAQ

Which is bigger, Definium Therapeutics or Altria Group?

Altria Group (MO) is larger, with a market capitalization of $115.85B compared with $4.71B for Definium Therapeutics (DFTX).

Which stock has performed better over the past year, DFTX or MO?

DFTX returned +193.15% over the past 12 months, compared with +3.96% for MO (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Definium Therapeutics or Altria Group?

Altria Group pays a dividend yielding 6.11%, while Definium Therapeutics does not currently pay a regular dividend.

Are Definium Therapeutics and Altria Group in the same industry?

Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.

More comparisons